E. Frair

PRMT5–PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells

Yeshavanth Banasavadi‐Siddegowda, Luke Russell, E. Frair et al. · Oncogene · 2016 · 124 citations · Full text

Neuro-oncology, Molecular Neuroscience, Primary Glioblastoma +10

Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce <i>DMD</i> Exon 2 Skipping

Liubov V. Gushchina, E. Frair, N. Rohan et al. · Human Gene Therapy · 2021 · 39 citations · Full text

A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2

Kevin M. Flanigan, Tatyana A. Vetter, Tabatha R. Simmons et al. · Molecular Therapy — Methods & Clinical Development · 2022 · 31 citations · Full text

Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse

Nicolas Wein, Tatyana A. Vetter, Adeline Vulin et al. · Molecular Therapy — Methods & Clinical Development · 2022 · 26 citations · Full text

Duchenne Muscular Dystrophy, Immunology, Aav9 Exon-skipping Vector +5

Automated immunofluorescence analysis for sensitive and precise dystrophin quantification in muscle biopsies

Tatyana A. Vetter, Stefan Nicolau, A. Bradley et al. · Neuropathology and Applied Neurobiology · 2021 · 20 citations · Full text